415 related articles for article (PubMed ID: 25453091)
1. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
Jiménez-Díaz MB; Ebert D; Salinas Y; Pradhan A; Lehane AM; Myrand-Lapierre ME; O'Loughlin KG; Shackleford DM; Justino de Almeida M; Carrillo AK; Clark JA; Dennis AS; Diep J; Deng X; Duffy S; Endsley AN; Fedewa G; Guiguemde WA; Gómez MG; Holbrook G; Horst J; Kim CC; Liu J; Lee MC; Matheny A; Martínez MS; Miller G; Rodríguez-Alejandre A; Sanz L; Sigal M; Spillman NJ; Stein PD; Wang Z; Zhu F; Waterson D; Knapp S; Shelat A; Avery VM; Fidock DA; Gamo FJ; Charman SA; Mirsalis JC; Ma H; Ferrer S; Kirk K; Angulo-Barturen I; Kyle DE; DeRisi JL; Floyd DM; Guy RK
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5455-62. PubMed ID: 25453091
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
3. A G358S mutation in the Plasmodium falciparum Na
Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
[TBL] [Abstract][Full Text] [Related]
4. Cation ATPase (ATP4) Orthologue Replacement in the Malaria Parasite Plasmodium knowlesi Reveals Species-Specific Responses to ATP4-Targeting Drugs.
Mohring F; van Schalkwyk DA; Henrici RC; Blasco B; Leroy D; Sutherland CJ; Moon RW
mBio; 2022 Oct; 13(5):e0117822. PubMed ID: 36190127
[TBL] [Abstract][Full Text] [Related]
5. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.
Spillman NJ; Kirk K
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):149-62. PubMed ID: 26401486
[TBL] [Abstract][Full Text] [Related]
6. Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
Gaur AH; Panetta JC; Smith AM; Dallas RH; Freeman BB; Stewart TB; Tang L; John E; Branum KC; Patel ND; Ost S; Heine RN; Richardson JL; Hammill JT; Bebrevska L; Gusovsky F; Maki N; Yanagi T; Flynn PM; McCarthy JS; Chalon S; Guy RK
EBioMedicine; 2022 Jun; 80():104065. PubMed ID: 35598441
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization and chemical inhibition of PfATP4-associated Na
Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
[TBL] [Abstract][Full Text] [Related]
8. Manipulating Eryptosis of Human Red Blood Cells: A Novel Antimalarial Strategy?
Boulet C; Doerig CD; Carvalho TG
Front Cell Infect Microbiol; 2018; 8():419. PubMed ID: 30560094
[TBL] [Abstract][Full Text] [Related]
9. Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones.
Chen Y; Zhu F; Hammill J; Holbrook G; Yang L; Freeman B; White KL; Shackleford DM; O'Loughlin KG; Charman SA; Mirsalis JC; Guy RK
Malar J; 2021 Feb; 20(1):107. PubMed ID: 33608015
[TBL] [Abstract][Full Text] [Related]
10. Antimalarials Targeting the Malaria Parasite Cation ATPase
Zagórska A; Jaromin A
Curr Top Med Chem; 2023; 23(3):214-226. PubMed ID: 36411573
[TBL] [Abstract][Full Text] [Related]
11. Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates.
Kreutzfeld O; Rasmussen SA; Ramanathan AA; Tumwebaze PK; Byaruhanga O; Katairo T; Asua V; Okitwi M; Orena S; Legac J; Conrad MD; Nsobya SL; Aydemir O; Bailey J; Duffey M; Bayles BR; Vaidya AB; Cooper RA; Rosenthal PJ
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0077121. PubMed ID: 34339273
[TBL] [Abstract][Full Text] [Related]
12. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.
Spillman NJ; Allen RJ; McNamara CW; Yeung BK; Winzeler EA; Diagana TT; Kirk K
Cell Host Microbe; 2013 Feb; 13(2):227-37. PubMed ID: 23414762
[TBL] [Abstract][Full Text] [Related]
13. Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice.
SheelaNair A; Romanczuk AS; Aogo RA; Haldar RN; Lansink LIM; Cromer D; Salinas YG; Guy RK; McCarthy JS; Davenport MP; Haque A; Khoury DS
Malar J; 2022 Feb; 21(1):49. PubMed ID: 35172826
[TBL] [Abstract][Full Text] [Related]
14. Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.
Crawford ED; Quan J; Horst JA; Ebert D; Wu W; DeRisi JL
PLoS One; 2017; 12(5):e0178163. PubMed ID: 28542423
[TBL] [Abstract][Full Text] [Related]
15. A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4.
Gilson PR; Kumarasingha R; Thompson J; Zhang X; Penington JS; Kalhor R; Bullen HE; Lehane AM; Dans MG; de Koning-Ward TF; Holien JK; Soares da Costa TP; Hulett MD; Buskes MJ; Crabb BS; Kirk K; Papenfuss AT; Cowman AF; Abbott BM
Sci Rep; 2019 Jul; 9(1):10292. PubMed ID: 31311978
[TBL] [Abstract][Full Text] [Related]
16. Diverse Chemical Compounds Target Plasmodium falciparum Plasma Membrane Lipid Homeostasis.
Bhatnagar S; Nicklas S; Morrisey JM; Goldberg DE; Vaidya AB
ACS Infect Dis; 2019 Apr; 5(4):550-558. PubMed ID: 30638365
[TBL] [Abstract][Full Text] [Related]
17. Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.
Turner H
Future Med Chem; 2016; 8(2):227-38. PubMed ID: 26824174
[TBL] [Abstract][Full Text] [Related]
18. Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy.
Deng X; Duffy SP; Myrand-Lapierre ME; Matthews K; Santoso AT; Du YL; Ryan KS; Ma H
Malar J; 2015 Oct; 14():428. PubMed ID: 26520795
[TBL] [Abstract][Full Text] [Related]
19. Diverse chemotypes disrupt ion homeostasis in the Malaria parasite.
Lehane AM; Ridgway MC; Baker E; Kirk K
Mol Microbiol; 2014 Oct; 94(2):327-39. PubMed ID: 25145582
[TBL] [Abstract][Full Text] [Related]
20.
Barnes CBG; Dans MG; Jonsdottir TK; Crabb BS; Gilson PR
Front Cell Infect Microbiol; 2022; 12():1060202. PubMed ID: 36530423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
